These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 29029524)

  • 1. Comparative efficacy and safety of antibody induction therapy for the treatment of kidney: a network meta-analysis.
    Shao M; Tian T; Zhu X; Ming Y; Iwakiri Y; Ye S; Ye Q
    Oncotarget; 2017 Sep; 8(39):66426-66437. PubMed ID: 29029524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis.
    Morgan RD; O'Callaghan JM; Knight SR; Morris PJ
    Transplantation; 2012 Jun; 93(12):1179-88. PubMed ID: 22660659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alemtuzumab versus antithymocyte globulin induction therapies in kidney transplantation patients: A systematic review and meta-analysis of randomized controlled trials.
    Zheng J; Song W
    Medicine (Baltimore); 2017 Jul; 96(28):e7151. PubMed ID: 28700465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
    Lü TM; Yang SL; Wu WZ; Tan JM
    Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of induction therapy with alemtuzumab in kidney transplantation: a meta-analysis.
    Shou ZF; Zhou Q; Cai JR; Cheng J; He Q; Wu JY; Chen JH
    Chin Med J (Engl); 2009 Jul; 122(14):1692-8. PubMed ID: 19719973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of induction modality on the outcome of deceased donor kidney transplant recipients discharged on steroid-free maintenance immunosuppression.
    Sureshkumar KK; Thai NL; Hussain SM; Ko TY; Marcus RJ
    Transplantation; 2012 Apr; 93(8):799-805. PubMed ID: 22290269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of alemtuzumab and daclizumab versus antithymocyte globulin during organ transplantation: a meta-analysis.
    Hao WJ; Zong HT; Cui YS; Zhang Y
    Transplant Proc; 2012 Dec; 44(10):2955-60. PubMed ID: 23195005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alemtuzumab induction and triple maintenance immunotherapy in kidney transplantation from donors after cardiac death.
    Schadde E; D'Alessandro AM; Knechtle SJ; Odorico J; Becker Y; Pirsch J; Sollinger H; Fernandez LA
    Transpl Int; 2008 Jul; 21(7):625-36. PubMed ID: 18397178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alemtuzumab induction in deceased donor kidney transplantation.
    Huang E; Cho YW; Hayashi R; Bunnapradist S
    Transplantation; 2007 Oct; 84(7):821-8. PubMed ID: 17984833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of maintenance steroids on the outcomes in deceased-donor kidney transplant recipients exposed to prolonged pretransplantation dialysis.
    Sureshkumar KK; Hussain SM; Thai NL; Marcus RJ
    Transplant Proc; 2013; 45(1):99-101. PubMed ID: 23375281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alemtuzumab with rapid steroid taper in simultaneous kidney and pancreas transplantation: comparison to induction with antithymocyte globulin.
    Reddy KS; Devarapalli Y; Mazur M; Hamawi K; Chakkera H; Moss A; Mekeel K; Post D; Heilman R; Mulligan D
    Transplant Proc; 2010; 42(6):2006-8. PubMed ID: 20692393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction with and without antithymocyte globulin combined with cyclosporine/tacrolimus-based immunosuppression in renal transplantation: a meta-analysis of randomized controlled trials.
    Tian JH; Wang X; Yang KH; Liu AP; Luo XF; Zhang J
    Transplant Proc; 2009 Nov; 41(9):3671-6. PubMed ID: 19917365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alemtuzumab induction in renal transplantation.
    Hanaway MJ; Woodle ES; Mulgaonkar S; Peddi VR; Kaufman DB; First MR; Croy R; Holman J;
    N Engl J Med; 2011 May; 364(20):1909-19. PubMed ID: 21591943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delayed allograft inflammation following alemtuzumab induction for kidney transplantation.
    Heilman RL; Khamash HA; Smith ML; Chakkera HA; Moss AA; Reddy KS
    Clin Transplant; 2013; 27(5):772-80. PubMed ID: 23924146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes Associated with Steroid Avoidance and Alemtuzumab among Kidney Transplant Recipients.
    Serrano OK; Friedmann P; Ahsanuddin S; Millan C; Ben-Yaacov A; Kayler LK
    Clin J Am Soc Nephrol; 2015 Nov; 10(11):2030-8. PubMed ID: 26342042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-2 receptor antagonist compared with antithymocyte globulin induction therapy in kidney transplantation from donors after cardiac death.
    Peng W; Liu G; Xie W; Huang H; Wu J; Shou Z; Chen J
    Int J Clin Pract Suppl; 2015 May; (183):23-8. PubMed ID: 26177071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction Therapies in Live Donor Kidney Transplantation on Tacrolimus and Mycophenolate With or Without Steroid Maintenance.
    Tanriover B; Zhang S; MacConmara M; Gao A; Sandikci B; Ayvaci MU; Mete M; Tsapepas D; Rajora N; Mohan P; Lakhia R; Lu CY; Vazquez M
    Clin J Am Soc Nephrol; 2015 Jun; 10(6):1041-9. PubMed ID: 25979971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alemtuzumab versus interleukin-2 receptor antibodies induction in living donor kidney transplantation.
    Sampaio MS; Kadiyala A; Gill J; Bunnapradist S
    Transplantation; 2009 Oct; 88(7):904-10. PubMed ID: 19935462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of alemtuzumab vs. antithymocyte globulin induction therapy in primary non-sensitized renal transplant patients treated with rapid steroid withdrawal.
    Saull HE; Enderby CY; Gonwa TA; Wadei HM
    Clin Transplant; 2015 Jul; 29(7):573-80. PubMed ID: 25711849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintenance immunosuppression with intermittent intravenous IL-2 receptor antibody therapy in renal transplant recipients.
    Gabardi S; Catella J; Martin ST; Perrone R; Chandraker A; Magee CC; McDevitt-Potter LM
    Ann Pharmacother; 2011 Sep; 45(9):e48. PubMed ID: 21811001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.